{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:19:18Z","timestamp":1777493958681,"version":"3.51.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/crd.0000000000000070","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T15:31:09Z","timestamp":1428075069000},"page":"201-211","source":"Crossref","is-referenced-by-count":18,"title":["Ivabradine"],"prefix":"10.1097","volume":"23","author":[{"given":"James J.","family":"Nawarskas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandi N.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe R.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.1945.02860430001001","article-title":"Transient tachycardia: prognostic significance alone and in association with transient hypertension.","volume":"129","author":"Levy","year":"1945","journal-title":"JAMA"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/oxfordjournals.aje.a113046","article-title":"Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies.","volume":"112","author":"Dyer","year":"1980","journal-title":"Am J Epidemiol"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: the Framingham Study.","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/0002-8703(93)90128-V","article-title":"Influence of heart rate on mortality among persons with hypertension: the Framingham Study.","volume":"125","author":"Gillman","year":"1993","journal-title":"Am Heart J"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1001\/archinte.162.20.2313","article-title":"Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension.","volume":"162","author":"Palatini","year":"2002","journal-title":"Arch Intern Med"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2105\/AJPH.91.8.1258","article-title":"Malattie Cardiovascolari Aterosclerotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project.","volume":"91","author":"Seccareccia","year":"2001","journal-title":"Am J Public Health"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1532-5415.2003.51080.x","article-title":"Resting heart rate in older people: a predictor of survival to age 85.","volume":"51","author":"Benetos","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0895-4356(00)00323-1","article-title":"Heart rate and mortality in a Japanese general population: an 18-year follow-up study.","volume":"54","author":"Fujiura","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.amjcard.2003.08.010","article-title":"Relation of heart rate at rest and mortality in the Womens Health and Aging Study.","volume":"92","author":"Chang","year":"2003","journal-title":"Am J Cardiol"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2796.2000.00602.x","article-title":"Heart rate and mortality.","volume":"247","author":"Reunanen","year":"2000","journal-title":"J Intern Med"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"ACCAHA Task Force Members. 2014 AHAACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of CardiologyAmerican Heart Association Task Force on Practice Guidelines.","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"R16-7-20210203","first-page":"e362","article-title":"American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines. 2013 ACCFAHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines.","volume":"127","author":"OGara","year":"2013","journal-title":"Circulation"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-9149(86)90234-1","article-title":"Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest.","volume":"58","author":"Gundersen","year":"1986","journal-title":"Am J Cardiol"},{"key":"R27-7-20210203","first-page":"689","article-title":"Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.","volume":"8","author":"Scicchitano","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"Pt 2","key":"R32-7-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.2005.100776","article-title":"Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.","volume":"572","author":"Bucchi","year":"2006","journal-title":"J Physiol"},{"key":"R33-7-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bjp.0706940","article-title":"Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity.","volume":"150","author":"Thollon","year":"2007","journal-title":"Br J Pharmacol"},{"key":"R34-7-20210203","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1476-5381.1996.tb15505.x","article-title":"Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.","volume":"118","author":"Bois","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"Pt 18","key":"R36-7-20210203","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1113\/jphysiol.2012.229435","article-title":"An updated computational model of rabbit sinoatrial action potential to investigate the mechanisms of heart rate modulation.","volume":"590","author":"Severi","year":"2012","journal-title":"J Physiol"},{"key":"R38-7-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000073933","article-title":"A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction.","volume":"100","author":"Manz","year":"2003","journal-title":"Cardiology"},{"key":"R41-7-20210203","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"R43-7-20210203","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3565(25)12114-9","article-title":"Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs.","volume":"275","author":"Simon","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R44-7-20210203","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00005344-200311000-00016","article-title":"Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs.","volume":"42","author":"Vilaine","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"R45-7-20210203","doi-asserted-by":"crossref","first-page":"H672","DOI":"10.1152\/ajpheart.00547.2001","article-title":"Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise.","volume":"282","author":"Colin","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R46-7-20210203","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","article-title":"Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.","volume":"109","author":"Mulder","year":"2004","journal-title":"Circulation"},{"key":"R47-7-20210203","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/FJC.0b013e31823e5e01","article-title":"Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.","volume":"59","author":"Fang","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"R48-7-20210203","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/eurheartj\/ehp554","article-title":"Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP1212.6 expression.","volume":"31","author":"Couvreur","year":"2010","journal-title":"Eur Heart J"},{"key":"R49-7-20210203","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/HYPERTENSIONAHA.111.183913","article-title":"Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and -receptor blockade.","volume":"59","author":"Becher","year":"2012","journal-title":"Hypertension"},{"key":"R50-7-20210203","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1161\/CIRCULATIONAHA.107.746537","article-title":"Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.","volume":"117","author":"Custodis","year":"2008","journal-title":"Circulation"},{"key":"R51-7-20210203","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bjp.2008.116","article-title":"Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice.","volume":"154","author":"Drouin","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R52-7-20210203","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000339547","article-title":"Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice.","volume":"49","author":"Custodis","year":"2012","journal-title":"J Vasc Res"},{"key":"R53-7-20210203","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JIM.0000000000000159","article-title":"Ivabradine on aortic stiffness in patients with heart failure.","volume":"63","author":"Nar","year":"2015","journal-title":"J Investig Med"},{"key":"R54-7-20210203","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"R55-7-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","article-title":"Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.","volume":"67","author":"Ruzyllo","year":"2007","journal-title":"Drugs"},{"key":"R58-7-20210203","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","article-title":"Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.","volume":"101","author":"Werdan","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"R59-7-20210203","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12325-015-0182-8","article-title":"Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.","volume":"32","author":"Werdan","year":"2015","journal-title":"Adv Ther"},{"key":"R60-7-20210203","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10557-011-6327-3","article-title":"Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina.","volume":"25","author":"Amosova","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"R66-7-20210203","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"R67-7-20210203","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2010.10.065","article-title":"BEAUTIFUL Investigators. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).","volume":"107","author":"Tendera","year":"2011","journal-title":"Am J Cardiol"},{"key":"R69-7-20210203","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"R70-7-20210203","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"},{"key":"R72-7-20210203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure.","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"R73-7-20210203","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R74-7-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/eurjhf\/hfs127","article-title":"Influence of background treatment with mineralocorticoid receptor antagonists on ivabradines effects in patients with chronic heart failure.","volume":"15","author":"Komajda","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R75-7-20210203","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"R76-7-20210203","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12325-015-0185-5","article-title":"Addition of ivabradine to -blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.","volume":"32","author":"Bagriy","year":"2015","journal-title":"Adv Ther"},{"key":"R77-7-20210203","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"key":"R81-7-20210203","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.25011\/cim.v32i5.6919","article-title":"Arrhythmic effects of ivabradine in patients with coronary artery disease.","volume":"32","author":"Murat","year":"2009","journal-title":"Clin Invest Med"},{"key":"R82-7-20210203","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials.","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T21:36:59Z","timestamp":1747863419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201507000-00007"}},"subtitle":["A Unique and Intriguing Medication for Treating Cardiovascular Disease"],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000070","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}